These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

868 related items for PubMed ID: 12734787

  • 1. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH, von Eye Corleta H, Capp E, Spritzer PM.
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [Abstract] [Full Text] [Related]

  • 2. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
    Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF.
    Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
    [Abstract] [Full Text] [Related]

  • 4. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J, Shen H, Li J, Huang Z, Zhang Y.
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [Abstract] [Full Text] [Related]

  • 5. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T, Dehghan-Kooshkghazi M.
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [Abstract] [Full Text] [Related]

  • 6. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
    Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH.
    Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
    [Abstract] [Full Text] [Related]

  • 7. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 Jan; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 8. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 9. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A, Agarwal N.
    J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
    [Abstract] [Full Text] [Related]

  • 10. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
    [Abstract] [Full Text] [Related]

  • 11. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L.
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [Abstract] [Full Text] [Related]

  • 12. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, Paşaoğlu H.
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [Abstract] [Full Text] [Related]

  • 13. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
    Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC.
    Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
    [Abstract] [Full Text] [Related]

  • 14. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [Abstract] [Full Text] [Related]

  • 15. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, Wyse EP.
    Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
    [Abstract] [Full Text] [Related]

  • 16. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
    Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS.
    Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293
    [Abstract] [Full Text] [Related]

  • 17. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
    Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S.
    Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
    [Abstract] [Full Text] [Related]

  • 18. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F.
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuçcu R.
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec 01; 123(2):204-11. PubMed ID: 16316811
    [Abstract] [Full Text] [Related]

  • 20. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr 01; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.